Director of Marketing & Communication
Field Application Specialist - AMERICAS
Director of Sales - West
Director Strategic Partnerships
Talk: Supporting viral vector therapies from PD to commercialization
The gene therapy industry is currently witnessing an unprecedented growth rate. Despite the rapid growth of the industry, several limitations remain with regarding the robust manufacture of viral vectors and the ability to efficiently produce increasingly larger volumes of finished product. Transient transfection of suspension cells is the most commonly used production platform for AAV manufacturing. However, this method shows some limitations for commercialization: inadequate transfection protocol, reduced transfection efficiency and lower productivity. To address this concern, we present data on Polyplus-transfection novel transfection reagent FectoVIR®-AAV showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducibility of viral titers at different production scale.
Presented by Géraldine GUERIN-PEYROU, Director of Marketing & Communication at Polyplus-transfection®
Talk available on demand for the duration of the virtual event.
Our solutions for both protein and virus production
NEW! FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.
PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.